In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) closed at $3.71 in the last session, down -0.54% from day before closing price of $3.73. In other words, the price has decreased by -$0.54 from its previous closing price. On the day, 1.25 million shares were traded. MRVI stock price reached its highest trading level at $3.76 during the session, while it also had its lowest trading level at $3.595.
Ratios:
We take a closer look at MRVI’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.56 and its Current Ratio is at 5.29. In the meantime, Its Debt-to-Equity ratio is 1.50 whereas as Long-Term Debt/Eq ratio is at 1.44.
Upgrades & Downgrades
In the most recent recommendation for the company, Robert W. Baird on February 26, 2025, Downgraded its rating to Neutral and sets its target price to $3 from $9 previously. Goldman Downgraded its Neutral to Sell on December 05, 2024, while the target price for the stock was maintained at $4.25.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 05 ’25 when LUCIER GREGORY T bought 51,472 shares for $3.70 per share. The transaction valued at 190,446 led to the insider holds 106,595 shares of the business.
LUCIER GREGORY T bought 48,528 shares of MRVI for $178,098 on Dec 08 ’25. The Director now owns 155,123 shares after completing the transaction at $3.67 per share. On Nov 13 ’25, another insider, Brust Bernd, who serves as the Chief Executive Officer of the company, bought 216,212 shares for $3.25 each. As a result, the insider paid 702,689 and bolstered with 466,771 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRVI now has a Market Capitalization of 1359310336 and an Enterprise Value of 848817408. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.93 while its Price-to-Book (P/B) ratio in mrq is 2.19. Its current Enterprise Value per Revenue stands at 4.411 whereas that against EBITDA is -10.481.
Stock Price History:
The Beta on a monthly basis for MRVI is 0.32, which has changed by -0.345679 over the last 52 weeks, in comparison to a change of 0.14045572 over the same period for the S&P500. Over the past 52 weeks, MRVI has reached a high of $6.21, while it has fallen to a 52-week low of $1.66. The 50-Day Moving Average of the stock is 10.52%, while the 200-Day Moving Average is calculated to be 41.50%.
Shares Statistics:
According to the various share statistics, MRVI traded on average about 1.52M shares per day over the past 3-months and 1266480 shares per day over the past 10 days. A total of 144.72M shares are outstanding, with a floating share count of 105.64M. Insiders hold about 27.15% of the company’s shares, while institutions hold 78.15% stake in the company. Shares short for MRVI as of 1764288000 were 12278685 with a Short Ratio of 8.06, compared to 1761868800 on 12985865. Therefore, it implies a Short% of Shares Outstanding of 12278685 and a Short% of Float of 10.0600004.
Earnings Estimates
. The current rating of Maravai LifeSciences Holdings Inc (MRVI) reflects the combined expertise of 10.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.05, with high estimates of -$0.02 and low estimates of -$0.09.
Analysts are recommending an EPS of between -$0.29 and -$0.34 for the fiscal current year, implying an average EPS of -$0.31. EPS for the following year is -$0.21, with 11.0 analysts recommending between -$0.15 and -$0.34.
Revenue Estimates
According to 10 analysts,. The current quarter’s revenue is expected to be $49.03M. It ranges from a high estimate of $49.6M to a low estimate of $48.7M. As of. The current estimate, Maravai LifeSciences Holdings Inc’s year-ago sales were $56.56MFor the next quarter, 10 analysts are estimating revenue of $50.6M. There is a high estimate of $65.81M for the next quarter, whereas the lowest estimate is $46M.
A total of 11 analysts have provided revenue estimates for MRVI’s current fiscal year. The highest revenue estimate was $187.7M, while the lowest revenue estimate was $184.62M, resulting in an average revenue estimate of $185.19M. In the same quarter a year ago, actual revenue was $259.19MBased on 10 analysts’ estimates, the company’s revenue will be $202.57M in the next fiscal year. The high estimate is $218.8M and the low estimate is $191.86M.
